Skip to main content
Erschienen in: International Ophthalmology 5/2023

31.10.2022 | COVID-19 | Original Paper

Posterior ocular manifestations following BNT162b2 mRNA COVID-19 vaccine: a case series

verfasst von: Shani Pillar, Tamar Weinberg, Radgonde Amer

Erschienen in: International Ophthalmology | Ausgabe 5/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To report the occurrence of posterior ocular adverse events following the administration of the BNT162b2 mRNA vaccine against SARS-CoV-2.

Methods

A retrospective consecutive case series, in which the medical files of patients presenting with ocular adverse events within 30 days of the vaccine inoculation, were analyzed.

Results

Four patients (2 females) were included in the study. The diagnoses included: posterior scleritis, paracentral acute middle maculopathy, herpes panuveitis, and Vogt–Koyanagi–Harada (VKH)-like uveitis. Three of the patients had no relevant ocular history, but the patient who developed scleritis was in remission without medical therapy for four years, until the flare-up, which occurred one day after the vaccine. All patients improved with treatment.

Conclusion

Though a causal relationship cannot be definitively established, the temporal relationship suggests a possible link between the COVID-19 vaccine and the posterior ocular complications. The benefits of vaccination clearly outweigh the potential adverse effects; however, ophthalmologists should be aware of the potential for vaccine-associated uveitis.
Literatur
1.
Zurück zum Zitat Polack FP, Thomas SJ, Kitchin N et al (2020) Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 383:2603–2615CrossRefPubMed Polack FP, Thomas SJ, Kitchin N et al (2020) Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 383:2603–2615CrossRefPubMed
2.
Zurück zum Zitat Ng XL, Betzler BK, Testi I et al (2021) Ocular adverse events after COVID-19 vaccination. Ocul Immunol Inflamm 29(6):1216–1224CrossRefPubMed Ng XL, Betzler BK, Testi I et al (2021) Ocular adverse events after COVID-19 vaccination. Ocul Immunol Inflamm 29(6):1216–1224CrossRefPubMed
3.
Zurück zum Zitat Rabinovitch T, Ben-Arie-Weintrob Y, Hareuveni-Blum T et al (2021) Uveitis after the BNT162b2 mRNA vaccination against SARS-CoV-2 infection: a possible association. Retina Phila Pa 41:2462–2471CrossRef Rabinovitch T, Ben-Arie-Weintrob Y, Hareuveni-Blum T et al (2021) Uveitis after the BNT162b2 mRNA vaccination against SARS-CoV-2 infection: a possible association. Retina Phila Pa 41:2462–2471CrossRef
4.
Zurück zum Zitat Neri P, Pichi F (2021) SARS-CoV-2 and the eye: the Pandora’s box of ocular immunology. J Ocul Pharmacol Ther 37(9):502–509CrossRefPubMed Neri P, Pichi F (2021) SARS-CoV-2 and the eye: the Pandora’s box of ocular immunology. J Ocul Pharmacol Ther 37(9):502–509CrossRefPubMed
5.
Zurück zum Zitat Neri P, Pichi F (2020) COVID-19 and the eye immunity: lesson learned from the past and possible new therapeutic insights. Int Ophthalmol 40(5):1057–1060CrossRefPubMedPubMedCentral Neri P, Pichi F (2020) COVID-19 and the eye immunity: lesson learned from the past and possible new therapeutic insights. Int Ophthalmol 40(5):1057–1060CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Pichi F, Aljneibi S, Neri P et al (2021) Association of ocular adverse events with inactivated COVID-19 vaccination in patients in Abu Dhabi. JAMA Ophthalmol 139(10):1131–1135CrossRefPubMedPubMedCentral Pichi F, Aljneibi S, Neri P et al (2021) Association of ocular adverse events with inactivated COVID-19 vaccination in patients in Abu Dhabi. JAMA Ophthalmol 139(10):1131–1135CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Moorthy RS, Moorthy MS, Cunningham ET (2018) Drug-induced uveitis. Curr Opin Ophthalmol 29:588–603CrossRefPubMed Moorthy RS, Moorthy MS, Cunningham ET (2018) Drug-induced uveitis. Curr Opin Ophthalmol 29:588–603CrossRefPubMed
8.
Zurück zum Zitat Thurairajan G, Hope-Ross MW, Situnayake RD et al (1997) Polyarthropathy, orbital myositis and posterior scleritis: an unusual adverse reaction to influenza vaccine. Br J Rheumatol 36:120–123CrossRefPubMed Thurairajan G, Hope-Ross MW, Situnayake RD et al (1997) Polyarthropathy, orbital myositis and posterior scleritis: an unusual adverse reaction to influenza vaccine. Br J Rheumatol 36:120–123CrossRefPubMed
9.
Zurück zum Zitat Sarraf D, Rahimy E, Fawzi AA et al (2013) Paracentral acute middle maculopathy: a new variant of acute macular neuroretinopathy associated with retinal capillary ischemia. JAMA Ophthalmol 131:1275–1287CrossRefPubMed Sarraf D, Rahimy E, Fawzi AA et al (2013) Paracentral acute middle maculopathy: a new variant of acute macular neuroretinopathy associated with retinal capillary ischemia. JAMA Ophthalmol 131:1275–1287CrossRefPubMed
10.
Zurück zum Zitat Chen X, Rahimy E, Sergott RC et al (2015) Spectrum of retinal vascular diseases associated with paracentral acute middle maculopathy. Am J Ophthalmol 160:26-34.e1CrossRefPubMed Chen X, Rahimy E, Sergott RC et al (2015) Spectrum of retinal vascular diseases associated with paracentral acute middle maculopathy. Am J Ophthalmol 160:26-34.e1CrossRefPubMed
11.
Zurück zum Zitat Virgo J, Mohamed M (2020) Paracentral acute middle maculopathy and acute macular neuroretinopathy following SARS-CoV-2 infection. Eye Lond Engl 34:2352–2353 Virgo J, Mohamed M (2020) Paracentral acute middle maculopathy and acute macular neuroretinopathy following SARS-CoV-2 infection. Eye Lond Engl 34:2352–2353
12.
Zurück zum Zitat Vinzamuri S, Pradeep TG, Kotian R (2021) Bilateral paracentral acute middle maculopathy and acute macular neuroretinopathy following COVID-19 vaccination. Indian J Ophthalmol 69:2862–2864CrossRefPubMedPubMedCentral Vinzamuri S, Pradeep TG, Kotian R (2021) Bilateral paracentral acute middle maculopathy and acute macular neuroretinopathy following COVID-19 vaccination. Indian J Ophthalmol 69:2862–2864CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Kluger N, Klimenko T, Bosonnet S (2022) Herpes simplex, herpes zoster and periorbital erythema flares after SARS-CoV-2 vaccination: 4 cases. Ann Dermatol Venereol 149(1):58–60CrossRefPubMed Kluger N, Klimenko T, Bosonnet S (2022) Herpes simplex, herpes zoster and periorbital erythema flares after SARS-CoV-2 vaccination: 4 cases. Ann Dermatol Venereol 149(1):58–60CrossRefPubMed
15.
Zurück zum Zitat Birabaharan M, Kaelber DC, Karris MY (2021) Risk of herpes zoster reactivation after mRNA COVID-19 vaccination: a cohort study. J Am Acad Dermatol S0190–9622(21):02892–02899 Birabaharan M, Kaelber DC, Karris MY (2021) Risk of herpes zoster reactivation after mRNA COVID-19 vaccination: a cohort study. J Am Acad Dermatol S0190–9622(21):02892–02899
16.
Zurück zum Zitat Alkhalifah MI, Alsobki HE, Alwael HM et al (2021) Herpes simplex virus keratitis reactivation after SARS-CoV-2 BNT162b2 mRNA Vaccination: a report of two cases. Ocul Immunol Inflamm 29(6):1238–1240CrossRefPubMed Alkhalifah MI, Alsobki HE, Alwael HM et al (2021) Herpes simplex virus keratitis reactivation after SARS-CoV-2 BNT162b2 mRNA Vaccination: a report of two cases. Ocul Immunol Inflamm 29(6):1238–1240CrossRefPubMed
17.
Zurück zum Zitat Rehman O, Ichhpujani P, Nayyar S et al (2021) COVID-19 pandemic and lockdown: changing trends in ophthalmology for in-patient and emergency services. Indian J Ophthalmol 69:701–705CrossRefPubMedPubMedCentral Rehman O, Ichhpujani P, Nayyar S et al (2021) COVID-19 pandemic and lockdown: changing trends in ophthalmology for in-patient and emergency services. Indian J Ophthalmol 69:701–705CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Mishra SB, Mahendradas P, Kawali A et al (2021) Reactivation of varicella zoster infection presenting as acute retinal necrosis post COVID 19 vaccination in an Asian Indian male. Eur J Ophthalmol 11206721211046484 Mishra SB, Mahendradas P, Kawali A et al (2021) Reactivation of varicella zoster infection presenting as acute retinal necrosis post COVID 19 vaccination in an Asian Indian male. Eur J Ophthalmol 11206721211046484
20.
Zurück zum Zitat Sood AB, O’Keefe G, Bui D et al (2019) Vogt–Koyanagi–Harada disease associated with hepatitis B vaccination. Ocul Immunol Inflamm 27:524–527CrossRefPubMed Sood AB, O’Keefe G, Bui D et al (2019) Vogt–Koyanagi–Harada disease associated with hepatitis B vaccination. Ocul Immunol Inflamm 27:524–527CrossRefPubMed
21.
Zurück zum Zitat Campos WR, Cenachi SPF, Soares MS et al (2021) Vogt–Koyanagi–Harada-like disease following yellow fever vaccination. Ocul Immunol Inflamm 29:124–127CrossRefPubMed Campos WR, Cenachi SPF, Soares MS et al (2021) Vogt–Koyanagi–Harada-like disease following yellow fever vaccination. Ocul Immunol Inflamm 29:124–127CrossRefPubMed
23.
Zurück zum Zitat Pereima RR, Bonatti R, Crotti F et al (2021) Ocular Adverse Events following yellow fever vaccination: a case series. Ocul Immunol Inflamm 1–5 Pereima RR, Bonatti R, Crotti F et al (2021) Ocular Adverse Events following yellow fever vaccination: a case series. Ocul Immunol Inflamm 1–5
24.
Zurück zum Zitat Gallagher MJ, Yilmaz T, Foster CS (2009) Vogt–Koyanagi–Harada syndrome associated with bilateral serous macular detachments responsive to immunomodulatory therapy. Ophthalmic Surg Lasers Imaging Off J Int Soc Imaging Eye 40:345–347 Gallagher MJ, Yilmaz T, Foster CS (2009) Vogt–Koyanagi–Harada syndrome associated with bilateral serous macular detachments responsive to immunomodulatory therapy. Ophthalmic Surg Lasers Imaging Off J Int Soc Imaging Eye 40:345–347
25.
Zurück zum Zitat Papasavvas I, Herbort CP (2021) Reactivation of Vogt–Koyanagi–Harada disease under control for more than 6 years, following anti-SARS-CoV-2 vaccination. J Ophthalmic Inflamm Infect 11:21CrossRefPubMedPubMedCentral Papasavvas I, Herbort CP (2021) Reactivation of Vogt–Koyanagi–Harada disease under control for more than 6 years, following anti-SARS-CoV-2 vaccination. J Ophthalmic Inflamm Infect 11:21CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Koong LR, Chee WK, Toh ZH et al (2021) Vogt–Koyanagi–Harada disease associated with COVID-19 mRNA vaccine. Ocul Immunol Inflamm 29(6):1212–1215CrossRefPubMed Koong LR, Chee WK, Toh ZH et al (2021) Vogt–Koyanagi–Harada disease associated with COVID-19 mRNA vaccine. Ocul Immunol Inflamm 29(6):1212–1215CrossRefPubMed
27.
Zurück zum Zitat Saraceno JJF, Souza GM, Dos Santos Finamor LP et al (2021) Vogt–Koyanagi–Harada syndrome following COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccine. Int J Retina Vitr 7:49CrossRef Saraceno JJF, Souza GM, Dos Santos Finamor LP et al (2021) Vogt–Koyanagi–Harada syndrome following COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccine. Int J Retina Vitr 7:49CrossRef
28.
Zurück zum Zitat Singh RB, Singh Parmar UP, Kahale F et al (2022) Vaccine-associated uveitis following SARS-CoV-2 vaccination: a CDC-VAERS database analysis. Ophthalmology S0161–6420(22):00672–00678 Singh RB, Singh Parmar UP, Kahale F et al (2022) Vaccine-associated uveitis following SARS-CoV-2 vaccination: a CDC-VAERS database analysis. Ophthalmology S0161–6420(22):00672–00678
29.
Zurück zum Zitat Tomkins-Netzer O, Sar S, Barnett-Griness O et al (2022) Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine and non-infectious uveitis: a population-based study. Ophthalmology 129(10):1087–1095CrossRefPubMed Tomkins-Netzer O, Sar S, Barnett-Griness O et al (2022) Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine and non-infectious uveitis: a population-based study. Ophthalmology 129(10):1087–1095CrossRefPubMed
Metadaten
Titel
Posterior ocular manifestations following BNT162b2 mRNA COVID-19 vaccine: a case series
verfasst von
Shani Pillar
Tamar Weinberg
Radgonde Amer
Publikationsdatum
31.10.2022
Verlag
Springer Netherlands
Schlagwort
COVID-19
Erschienen in
International Ophthalmology / Ausgabe 5/2023
Print ISSN: 0165-5701
Elektronische ISSN: 1573-2630
DOI
https://doi.org/10.1007/s10792-022-02565-2

Weitere Artikel der Ausgabe 5/2023

International Ophthalmology 5/2023 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Metastasen Leitthema

Orbitale und periokuläre metastatische Tumoren galten früher als sehr selten. Aber mit der ständigen Aktualisierung von Medikamenten und Nachweismethoden für die Krebsbehandlung werden neue Chemotherapien und Strahlenbehandlungen eingesetzt. Die …

Staging und Systemtherapie bei okulären und periokulären Metastasen

Metastasen Leitthema

Metastasen bösartiger Erkrankungen sind die häufigsten Tumoren, die im Auge diagnostiziert werden. Sie treten bei ungefähr 5–10 % der Patienten mit soliden Tumoren im Verlauf der Erkrankung auf. Besonders häufig sind diese beim Mammakarzinom und …

CME: Wundheilung nach Trabekulektomie

Trabekulektomie CME-Artikel

Wird ein Glaukom chirurgisch behandelt, ist die anschließende Wundheilung von entscheidender Bedeutung. In diesem CME-Kurs lernen Sie, welche Pathomechanismen der Vernarbung zugrunde liegen, wie perioperativ therapiert und Operationsversagen frühzeitig erkannt werden kann.

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Metastasen Leitthema

Peri- sowie intraokuläre Metastasen sind insgesamt gesehen selten und meist Zeichen einer fortgeschrittenen primären Tumorerkrankung. Die Therapie ist daher zumeist palliativ und selten kurativ. Zudem ist die Therapiefindung sehr individuell. Die …

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.